These findings, together with the overall expression profiles of MXD3 in primary tumors and pathological and metastatic stages, suggest its involvement at all stages of tumor progression, and hence it can serve as an attractive target for cancer therapies. The gene discussed is MXD3; the disease is neoplasm.